2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
matters addressed in this Item 2 that are not historical information constitute “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
including statements about any of the following: any projections of earnings, revenue, gross profit, cash, effective tax rate,
use of net operating losses, or any other financial items; the plans, strategies and objectives of management for future operations
or prospects for achieving such plans; and any statements of assumptions underlying any of the foregoing. Any statements contained
herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “seeks,”
“estimates,” and similar expressions are intended to identify forward-looking statements. While BioTime may elect
to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if BioTime’s
estimates change, and readers should not rely on those forward-looking statements as representing BioTime’s views as of
any date subsequent to the date of the filing of this Quarterly Report. Although we believe that the expectations reflected in
these forward-looking statements are reasonable, such statements are inherently subject to risks and BioTime can give no assurances
that its expectations will prove to be correct. Actual results could differ materially from those described in this Quarterly
Report because of numerous factors, many of which are beyond the control of BioTime. A number of important factors could cause
the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed
under the heading “Risk Factors” in Part I, Item 1A of BioTime’s Form 10-K, as amended, for the year ended December
following discussion should be read in conjunction with BioTime interim condensed consolidated financial statements and the related
notes provided under “Item 1- Financial Statements” above.
and Business Overview
are a clinical-stage biotechnology company targeting degenerative diseases. Our programs are based on two proprietary core technology
platforms: cell replacement and cell/drug delivery. With the cell replacement platform, we are producing new cells and tissues
with our pluripotent and progenitor cell technologies. These cells and tissues are developed to replace those that are either
rendered dysfunctional or lost due to degenerative diseases or injuries. Our cell/drug delivery programs are based upon our proprietary
HyStem® cell and drug delivery matrix technology. HyStem® was designed to provide
for the transfer, retention, and/or engraftment of cell replacement therapies and to act as a device for localized drug
lead cell replacement clinical product is OpRegen®, a retinal pigmented epithelium (RPE) cell replacement
therapy, which is in a Phase I/IIa multicenter trial for the treatment of late-stage, dry age-related macular degeneration (dry-AMD).
There are currently no FDA-approved therapies for dry-AMD, which accounts for approximately 90% of all age-related macular degeneration
cases, and is the leading cause of blindness in people over the age of 60.
Our lead cell delivery
clinical product, based on its proprietary HyStem® technology, is Renevia®, a potential
treatment for facial lipoatrophy. “Lipoatrophy” means the loss of fat tissue, which can be caused by several factors,
including trauma, aging, or drug side effects, such as those that cause HIV-associated lipoatrophy. We are also developing HyStem®
for the sustained delivery of therapeutic drugs and targeted cells to specific areas of the body.
2017, we formed AgeX Therapeutics, Inc. (“AgeX”) to
continue development of early-stage programs focusing on the development of regenerative
medicine technologies targeting the diseases of aging and metabolic disorders. AgeX’s initial programs focus on utilizing
brown adipose tissue (“brown fat”) in targeting diabetes, obesity, and heart disease; and induced tissue regeneration
(“iTR”) in utilizing the human body’s own abilities to scarlessly regenerate tissues damaged from age or trauma.
AgeX may also pursue other early-stage programs. We own approximately 85% of the issued and outstanding shares of AgeX
principal consolidated subsidiaries are AgeX, Cell Cure Neurosciences, Ltd (“Cell Cure”), ES Cell International, Pte
Ltd (“ESI”), LifeMap Sciences, Inc. (“LifeMap Sciences”), OrthoCyte Corporation (“OrthoCyte”),
and ReCyte Therapeutics, Inc. (“ReCyte”).
also have significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (“Asterias”),
and OncoCyte Corporation (“OncoCyte”), which we founded and which, until recently, were our majority-owned consolidated
subsidiaries. Asterias (NYSE American: AST) is presently focused on advancing three clinical-stage programs that have the potential
to address areas of very high unmet medical needs in the fields of neurology (spinal cord injury) and oncology (Acute Myeloid
Leukemia and lung cancer). OncoCyte (NYSE American: OCX) is developing confirmatory diagnostic tests for lung cancer, breast cancer,
and bladder cancer utilizing novel liquid biopsy technology. Beginning on May 13, 2016 and February 17, 2017, we deconsolidated
the financial statements and results of operations of Asterias and OncoCyte, respectively, from BioTime. As of March 31, 2018,
we owned 14,674,244 shares of OncoCyte common stock with a value of approximately $30.8 million and 21,747,569 shares of Asterias
common stock with a value of approximately $31.5 million.